JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $400

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $420 to $400.